+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
[PRM35] INCREMENTAL COST EFFECTIVENESS RATIO (ICER) THRESHOLD, THE END OF HORIZONTAL EQUITY?
Home
Publications
[PRM35] INCREMENTAL COST EFFECTIVENESS RATIO (ICER) THRESHOLD, THE END OF HORIZONTAL EQUITY?
Back Home
[PRM35] INCREMENTAL COST EFFECTIVENESS RATIO (ICER) THRESHOLD, THE END OF HORIZONTAL EQUITY?
2018 ISPOR Europe
Clay, E. | Aballea, S. | Francois, C. | Toumi, M. |
Volume: , Issue: , Pages: ,
The website uses cookies.
Learn More
Ok
